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Kratak sadr`aj: Akutni koronarni sindrom predstavlja vo -
de}i uzrok hospitalizacija i smrti. Rezultati skora{njih stu dija
pokazuju da se u proceni koronarnog rizika bolje po ka zalo
merenje apolipoproteina i apoB:apoA-I nego tradicio nal nih
lipida. Uporedili smo koncentracije apolipoproteina i
apoB:apoA-I sa tradicionalnim lipidskim merama i atero -
genim indeksima kod pacijenata sa dijagnozom akutnog
koronarnog sindroma (ACS) u roku od 6 sati od nastanka
bola u grudima. Prou~avanu grupu ~inilo je 227 pacijenata
sa dijagnozom ACS (STEMI=60, NSTEMI=66 i nestabilna
angina pektoris=105). Klini~ki zdravi dobrovoljci (n=85)
slu`ili su kao kontrola. Izmereni su sr~ani TnI, lipidski profil,
hsCRP, apolipoprotein A-I i apoB100 i izra~unati odnosi
apoB:apoA-I, TC-HDL-C, LDL-C:HDL-C. Pacijenti su imali
povi{en LDL-C (>3,0 mmol/L) i ne-HDL-C (>3,4 mmol/L).
Trigliceridi su bili ispod cut-off vrednosti, ali pacijenti su
ima li zna~ajno vi{e koncentracije TG i ni`i HDL-C u pore |e -
nju sa kontrolama (p<0,001). Koncentracija apo B i apoA-
I kod pacijenata ostala je u okviru prihva}enog opsega.
Aterogeni indeksi TC:HDL-C, LDL-C:HDL-C i apoB:apoA-I
bili su zna~ajno vi{i kod pacijenata. Odnos apoB:apoA-I
kod mu{karaca sa ACS ukazivao je na nizak rizik, dok je kod
`ena odgovarao srednjem riziku. Odnosi apoB:apoA-I i
LDL-C:HDL-C bili su dijagnosti~ki korisni za razlikovanje
pacijenata od kontrola (AUC 0,71 i 0,79). ApoB:apoA-I i
LDL-C:HDL-C bili su veoma dijagnosti~ki korisni za diskri -
minaciju izme|u pacijenata sa STEMI i kontrola (AUC 0,80
i 0,84). Nismo uspeli da poka`emo superiornost apoB-
Address for correspondence:
Grazyna Sypniewska
Department of Laboratory Medicine
M. Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland
e-mail: odesªcm.umk.pl
Abbreviations: STEMI – ST-elevation myocardial infarction,
NSTEMI – non-ST-elevation myocardial infarction, UA –
unstable angina pectoris
Summary: Acute coronary syndromes are the leading
cause of hospitalization and death. Results from recent stu -
dies suggest that apolipoprotein measurement and apoB:
apoA-I are superior to traditional lipids in the estimation of
coro nary risk. We compared apolipoprotein concentrations
and apoB:apoA-I with traditional lipid measures and athe ro -
genic indices in patients diagnosed with acute coronary
syndromes (ACS) within 6 hrs from the onset of chest pain.
A study group consisted of 227 patients diagnosed with ACS
(STEMI=60, NSTEMI=66 and UA=105). Clinically healthy
volunteers (n=85) served as controls. Measure ments of
cardiac TnI, lipid profile, hsCRP, apolipoprotein A-I and
apoB100 were performed and apoB:apoA-I, TC-HDL-C,
LDL-C:HDL-C ratios were calculated. Patients had increased
LDL-C (>3.0 mmol/L) and non-HDL-C (>3.4 mmol/L).
Triglycerides were below the cut-off value, but patients had
significantly higher TG concentrations and lower HDL-C
compared to controls (p<0.001). Apo B and apoA-I con -
cen tration in patients remained within the accepted range.
Atherogenic indices TC:HDL-C, LDL-C:HDL-C and apoB:
apoA-I were significantly increased in patients. ApoB:apoA-I
ratio in ACS males was within low risk whereas in females
corresponded to medium risk. ApoB:apoA-I and LDL-C:HDL-
C ratios were of good diagnostic utility for discrimination
between patients and controls (AUC 0.71 and 0.79; respec -
tively). ApoB:apoA-I and LDL-C:HDL-C were of very good
diagnostic utility for discrimination between STEMI patients
and controls (AUC 0.80 and 0.84). We could not show the
superiority of apoB:apoA-I over LDL-C:HDL-C as the discr i -
Introduction
According to data published in the National Reg -
istry of Acute Coronary Syndromes (PL-ACS) every
year in Poland 140.000 subjects are diagnosed with
acute coronary syndromes (ACS) (1). Acute coronary
syndromes are a group of disorders developing as a
consequence of atherosclerosis and characterized by
changes in the coronary circulation, whose common
feature is the significant reduction or cessation of
blood flow in the coronary arteries. The most com -
mon cause of circulatory disorders is a blood clot
formed at the rupture of atherosclerotic plaque. No vel
cardiac biomarkers are used to identify patients with
ACS even when there is no evidence of cardio my ocyte
damage (myeloperoxidase, ischemia-modi fied albu -
min, heart-fatty acid binding protein). Simi la rly, novel
biomarkers are assessed that may be re gar ded as risk
discriminators of cardiovascular disease (CVD) with a
predictive value for future events. Apolipoprotein B
(apo B) and apolipoprotein A-I (apo A-I), either sepa -
rately or together as a cal cu lated apoB:apoA-I ratio,
may predict CVD risk more accurately than traditional
lipid pro file measurement.  
Each proatherogenic lipoprotein fraction: VLDL,
IDL, and LDL contains one apo B molecule per par -
ticle, therefore the serum concentration of apo B re -
flects the total number of atherogenic particles (2).
HDL is the only antiatherogenic lipoprotein and its
major structural protein is apo A-I. This protein pro -
duced both in the liver and intestine is involved in
reverse cholesterol transport carrying excess choles -
terol from peripheral tissues back to the liver for ex -
cretion (3).
In spite of the availability of standardized com -
mer cial assays, apo B and/or apoA-I are not yet widely
measured in routine medical laboratory prac tice. Data
sug gest that measurement of apo B po ten tially could
pro vide several advantages over the con ventional
measu re ment of LDL-cholesterol (LDL-C) and non-
HDL-C as a cardiovascular disease risk in dex. Apo B
can be mea sured directly and with a high accuracy
and pre cision in the nonfasting state (4). The reliability
and reproducibility of apo B assays are comparable to
those expected for non-HDL-C, a meas ure of all the
cholesterol in atherogenic lipo proteins (5).
The optimal value for LDL-cholesterol (LDL-C) is
<2.6 mmol/L, for non-HDL-C it is <3.4 mmol/L and
the opti mal apo B concentration is <0.9 g/L (6).
Results above these values indicate an increased risk
of CVD including acute coronary syndromes. Even
the most accurate determinations of LDL-C or non-
HDL-C, obta ined after calculation of other para me -
ters, do not fully reflect the proatherogenic impact of
apo B containing lipoproteins. Studies showed that in
sub jects with normal or slightly increased concen -
trations of LDL-C, apo B is a better indicator of CVD
risk. This comes from the fact that even with a slightly
elevated concentration of LDL-C in the blood, with
conco mittant hypertriglyceridemia and low HDL-C,
very often an increase of small dense LDL particles
occurs (7). Small dense LDL have up to 25% lower
cho lesterol content per one apo B molecule than
large LDL particles (8). Cardiovascular risk is more
directly related to the number and size of atherogenic
parti cles than to their cholesterol concentration (4, 7, 9).
The concentration of apo AI in the circulation is
approximately 1–1.3 g/L, and the majority of this
protein (99%) is a part of HDL. Concentration of apo
A-I below 1.2 g/L is related to greater risk of CVD (10).
The cholesterol content of HDL particles is influ enced
by blood triglyceride concentration and in, general,
hypertriglyceridemia is associated with low HDL-C and
low apo A-I values (11, 12). The most use ful as a
predictor of CVD risk seems to be the cal culated
apoB:apoA-I ratio (13). Previous reports have shown
that an apoB:apoA-I ratio of <0.7 and <0.6 for men
and women respectively is associated with low risk for
cardiovascular disease. ApoB:apoA-I corresponds to
the relationship between proathero genic apo B-con -
taining lipoproteins and anti-athero genic HDL fraction
(13). The advantage of calcula ting this ratio is that the
concentrations of both apo lipoproteins are not influ -
 enced by a nonfasting state and during daytime. In
addi tion, with regard to the tests performed after acute
coronary syndromes have occurred, it does not matter
how much time has elap sed since the blood collection.
This is a valuable piece of information, because in pa -
tients sus pected with ACS the credibility of lipid mea -
surement is questioned if the blood was collected
within 24 hours after the incident.  
Results from recent studies suggested that the
se rum concentration of apo B and apo A-I as well as
the apoB:apoA-I ratio are related to the occurrence of
ACS in different ethnic populations (8). We aimed to
com pare apolipoprotein concentrations and the apoB:
apoA-I ratio with the traditional lipid measures in
patients diag nosed with acute coronary syndromes.
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mination power of both was almost identical. Determination
of apolipoproteins should not be recommended for routine
clinical use, however, incorporating apoB and apoB:apoA-I
into risk assessment could provide additional important
information on cardiovascular risk. 
Keywords: acute coronary syndromes, apolipoproteins,
cardiovascular risk
apoA-I u odnosu na LDL-C:HDL-C po{to je njihova diskri -
minatorna mo} gotovo identi~na. Odre|ivanje apolipo pro -
teina ne bi trebalo preporu~ivati za rutinsku klini~ku upo -
trebu, me|utim, uklju~ivanje apoB i apoB:apoA-I u procenu
rizika moglo bi obezbediti dodatne va`ne informacije o kar -
dio vaskularnom riziku. 
Klju~ne re~i: akutni koronarni sindromi, apolipoproteini,
kardiovaskularni rizik
Materials and Methods
A study group consisted of 103 women (aged
69±10 years) and 146 men (aged 61±13 years) who
were admitted to the Department of Cardiology and
Internal Medicine of the University Hospital bet ween
September 2008 and March 2009. All patients
presented with chest pain initiating within 6 hours
before the hospital admission. Electrocardiography
exa mination was performed on admission and the re -
after if clinically indicated. Echocardiography, stress
tests and cardiac catheterization were performed if
needed. Altogether 227 patients were finally diag -
 nosed with ACS and 22 patients as having other heart
disease or unspecified chest pain. ACS patients were
subsequently definitely diagnosed with unstable angina
(UA n=105), non-ST-elevation myocardial infarction
(NSTEMI n=66) or ST-elevation myocardial infarction
(STEMI n=60). Patients with heart failure, pulmonary
embolism, chronic obstructive pulmonary disease,
renal insufficiency, myocardial infarction wit hin 6 weeks
preceding the enrolment were excluded from the trial. 
Clinically healthy volunteers (34 females, aged
54±4 years and 51 males, aged 50±7 years) with no
evidence of present renal, metabolic or inflammatory
disease, heart failure and recent myocardial infarction
served as controls. Hypertension was diagnosed if sys -
tolic blood pressure exceeded 140 mmHg and/or
diastolic blood pressure was above 90 mmHg, and
dyslipidaemia if even one of the lipid profile com po -
nents was above/under the following values: total
cholesterol (TC) >4.9 mmol/L, triglycerides (TG) >1.7
mmol/L, LDL-C>3.0 mmol/L, HDL-cholesterol (HDL-
C) <1.3/<1.0 mmol/L females/males accor ding to
ESH/ESC recommendations. Non-HDL-C over 3.4
mmol/L was accepted as elevated. Among subjects in
the control group, 30% had slightly elevated TC and/or
LDL-C and 5% had decreased HDL-C. 
The study protocol was approved by the Bio et hics
Committee at Nicolaus Copernicus University in Torun
Collegium Medicum in Bydgoszcz and written informed
consent has been obtained from all patients. 
Venous blood samples were collected from
patients on hospital admission within 6 hours of the
chest pain onset. From controls fasting venous blood
samples were collected in the morning. Serum was
assayed on admission for cTnI, lipid parameters,
glucose, hsCRP and BNP (Architect ci8200, Abbott
Diagnostics). LDL-C and non-HDL-C were calculated.
Any increase of cTnI above 0.032 ng/mL (the 99th
percentile for the healthy population measured with
10% CV) was considered a positive result. Serum
apoA-I and apo B100 concentrations were measured
in samples stored frozen at –80 °C not longer than 6
months (Abbott ARCHITECT ci8200) and the ratio of
apoB:apoA-I was calculated. ApoB concentration
>0.9 g/L was accepted as elevated, whereas apoA-I
<1.2 g/L was accepted as decreased. ApoB:apoAI
ratio <0.3/0.4 and LDL-C:HDL-C <2.3/<2.9 for
females/males and TC:HDL-C <4/<5 for females
/males were accepted as optimal. According to Wall -
dius et al. (12) apoB:apoA-I ratio within 0.3–0.6 or
0.4–0.7 for females/males was consi dered as low
risk; 0.6–0.8 or 0.7–0.9 was considered as medium
risk and >0.8/>0.9 for females/males as high risk of
myocardial infarction.
Statistical methods
Data were presented as medians and 25th and
75th percentiles. U-Mann-Whitney test and ANOVA
were used to compare differences. ROC analysis was
performed and AUC were calculated. Statistical ana l -
ysis was performed using Statistica 8.0 for Windows.
Results
Tables Ia,b show the general characteristics of the
study groups. The most distinctive feature of both fe -
males and males with ACS was increased LDL-C
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Parameter ACS patients (Females n=94) Control group (Females n=34)
Age (years) 68.8±9.9 54±3a
TC (mmol/L) 5.03 (4.23–6.0) 4.72 (4.46–5.0)b
HDL-C (mmol/L) 1.16 (1.0–1.42) 1.6 (1.44–1.78)a
non-HDL-C 3.95 (3.09–4.54) 3.09 (2.71–3.38)a
TC:HDL-C 4.3 (3.5–4.8) 2.9 (2.6–3.2)a
LDL-C (mmol/L) 3.2 (2.53–3.95) 2.63 (2.42–2.97)b
LDL-C:HDL-C 2.63 (1.99–3.29) 1.62 (1.41–1.85)a
TG (mmol/L) 1.29 (1.0–1.75) 0.84 (0.69–1.09)a
apoA-I (g/L) 1.32 (1.14–1.48) 1.58 (1.41–1.66)a
apoB (g/L) 0.8 (0.64–0.97) 0.72 (0.62–0.80)
apoB:apoA-I 0.62 (0.5–0.75) 0.47 (0.42–0.53)a
Table Ia Characteristics of the study groups (females).
a: p<0.001 ACS and control group; b: p<0.05 ACS and control group
(>3.0 mmol/L) and non-HDL-C (>3.4 mmol/L). Al -
though median concentration of triglycerides was found
to be below the cut-off value, patients diag nosed with
ACS had significantly higher TG concen tration and low -
er HDL-C compared to controls (p<0.001). Me d ian
apo B concentration in ACS pati ents remained within
the accepted optimal range, but in a group of males
was significantly higher than in controls. Similarly, me -
dian apo A-I concentration in ACS patients was within
the optimal range but in females was lower than in res -
pective controls (p<0.001).  
Atherogenic indices TC:HDL-C, LDL-C:HDL-C
and apoB:apoA-I were significantly increased in pa -
tients with ACS compared to controls. Median TC:
HDL-C and LDL-C:HDL-C in males diagnosed with
ACS were found to be close to the cut-off value, but
they were over the cut-off in females. Increased CVD
risk in females, reflected by TC:HDL-C >4 and LDL-
C:HDL-C >2.3, was found in 61% and 64.5%, res -
pec tively, whereas in males a ratio TC:HDL-C >5 and
LDL-C:HDL-C >2.9 was observed in 42% and 50.3%,
respectively.
Median apoB:apoA-I ratio in ACS males was in
the range of low risk whereas in females this ratio
corresponded to medium risk. In females diagnosed
with ACS increased CVD risk reflected by an apoB:
apoA-I ratio >0.6 was found in 58% and in males an
apoB:apoA-I ratio >0.7 was observed in 50%.
In ACS patients better correlation was observed
for non-HDL-C and apoB concentration (r= 0.74 in
females and r=0.85 in males; p<0.001) than for LDL-
C and apo B, whereas the correlation of apoB:apoA-I
ratio with both TC:HDL-C or LDL-C:HDL-C was si milar
(r=0.74 in females and r= 0.84 in males; p<0.001). 
ROC analysis was performed for all atherogenic
indices, LDL-C, HDL-C, non-HDL-C, apo B and apo
A-I, to discriminate between patients with ACS diag -
nosis and controls and the best discriminators were
cho sen. Both the calculated apoB:apoA-I and LDL-
C: HDL-C ratios were of good diagnostic utility for the
dis crimination between patients diagnosed with ACS
and controls (areas under the ROC curve–AUC were
0.71 and 0.79; respectively) (Table II).
Among others, non-HDL-C was a slightly better
discriminator than apo B alone (AUC 0.72 and 0.66;
respectively).
Table III shows the characteristics of the ACS
group according to the clinical diagnosis. The diffe r -
ences between most measured parameters, in ACS
patients with different clinical diagnosis, did not reach
statistical significance, excluding the LDL-C concen -
tra tion and apoB:apoA-I value that were the highest
in patients with the diagnosis of STEMI (p<0.05).
Patients with STEMI had also the highest median
apoB con centration. Furthermore, in 46% of patients
with STEMI the highest apoB:apoAI values (top ter -
tile), from 0.65–1.29 in females and 0.8–1.45 in ma -
les, were observed, while in 30–40% of those with UA
and NSTEMI the lowest values (in the lowest tertile)
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Parameter ACS patients (Males n=133) Control group (Males n=51)
Age (years) 61.4±13.3 50.2±7.1b
TC (mmol/L) 4.85 (4.02–5.98) 4.54 (4.02–4.95)b
HDL-C (mmol/L) 1.0 (0.9–1.21) 1.34 (1.13–1.47)a
non-HDL-C 3.82 (2.99–4.72) 3.2 (2.6–3.53)a
TC:HDL-C 4.5 (4.0–5.7) 3.5 (2.69–3.8)a
LDL-C (mmol/L) 3.15 (2.29–3.87) 2.71 (2.14–3.15)b
LDL-C:HDL-C 2.86 (2.43–3.78) 2.1 (1.6–2.5)a
TG (mmol/L) 1.39 (1.02–2.07) 1.16 (0.71–1.32)a
apoA-I (g/L) 1.22 (1.07–1.37) 1.25 (0.98–1.43)a
apoB (g/L) 0.81 (0.67–1.02) 0.67 (0.54–0.85)a
apoB:apoA-I 0.68 (0.55–0.84) 0.55 (0.46–0.66)a
Table Ib  Characteristics of the study groups (males).
a: p<0.001 ACS and control group; b: p<0.05 ACS and control group
Table II Diagnostic utility of selected parameters mea sured

















from 0.29–0.51 and 0.27–0.60 for females and ma -
les, respectively, were found (results not shown). This
was not observed for other atherogenic indexes. 
The calculated apoB:apoA-I and LDL-C:HDL-C
ra tios were of very good diagnostic utility for the
discri mination between patients and controls only in
the STEMI group (AUC were 0.80 and 0.84; res -
pectively) (Table II). Among others, non-HDL-C, apoB
and LDL-C had a good discrimination power. 
Discussion
In this study, performed in patients presenting
with chest pain and further diagnosed with ACS, we
aimed to evaluate whether apolipoproteins B and A-I
and the apoB:apoA-I ratio perform better than tra -
ditional lipids and atherogenic indices in the asses s -
ment of risk associated with cardiovascular incidents.
Some previous studies have shown that the higher the
value of apoB:apoA-I, the higher the risk of incident
cardio vascular events (13, 14). We have shown in pa -
tients with diagnosed ACS that the apoB:apoA-I ratio
was of good diagnostic utility for the discrimi na tion
between ACS cases and control subjects (AUC=0.71)
and even very good to distinguish STEMI cases which
are at the greatest risk (AUC=0.80). However, we
could not show the superiority of this ratio over the
cal culated LDL-C:HDL-C as the discrimination power
of both was almost identical. This is further confirmed
by the comparison of estimated CVD risk in ACS
patients with the use of apoB:apoA-I ratio and the
calculated athe rogenic indices TC:HDL-C and LDL-
C:HDL-C. The per centage of patients with increased
CVD risk was almost the same in females and in ma -
les irres pective of the ratio used. 
Considering the results of our study, only LDL-C
and non-HDL-C concentrations in ACS patients were
elevated over the accepted cut-off values, whereas
the other measured parameters, even though higher
or lower (HDL-C, apoA-I) compared to controls, re -
mai ned within the accepted optimal range. Patients
diag nosed with ACS had, in general, moderately
higher TG concentrations and decreased HDL-C
compared to controls, which allow to assume the
occurrence of small dense LDL particles to a relatively
small extent. In fact, an elevated apoB concentration
over 0.9 g/L in our group of ACS patients was obser -
ved only in 33.6%, distributed equally among females
and males. It was reported earlier that apoB is more
closely asso ciated with metabolic syndrome, hyper -
insuli ne mia and insulin-resistance than the LDL-C
concentration (15). In our ACS patients the fre quency
of diabetes mellitus was 50% and the main clinical
feature was hyper tension (74%) which may probably
explain the relatively low occurrence of elevated apoB
in this setting. 
It has been demonstrated in one of the first
AMORIS studies, that the coronary risk and mortality
due to coronary heart disease are associated with
high apoB and higher values of apoB:apoA-I, and that
this relationship is stronger than that for LDL-C (13,
16). Other subsequent studies, including EPIC-Nor -
folk study, ULSAM and the MONICA/Cora confirmed
that the apoB:apoAI ratio is a useful index of both
nonfatal and fatal myocardial infarction (MI) (13).
Furthermore, the INTERHEART study showed that
the ratio of apoB to apoA-I was not only the strongest
risk factor in predicting MI, but was also the most
prevalent risk factor of all risk factors in de pendent of
age, sex and ethnicity (8). Taking into account the
differences between the ACS groups in our study,
according to clinical diagnosis, the highest apoB:
apoAI ratio was observed predominantly in STEMI
patients. On the contrary, the lowest values of the
ratio were found predominantly among patients with
UA and NSTEMI. From a clinical point of view this is
confirmed by the results of recently published studies
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Table III Characteristics of the ACS patients according to the clinical diagnosis.
Parameter STEMI (n=60) NSTEMI (n=66) UA (n=105)
Age (years) 64.4±12.5 67.3±14 63.1±11.1
TC (mmol/L) 5.21 (4.46–6.24) 4.82 (4.12–5.75) 4.82 (3.92–5.98)
HDL-C (mmol/L) 1.11 (0.93–1.31) 1.13 (0.93–1.31) 1.08 (0.93–1.31)
n-HDL-C (mmol/L) 4.02 (3.46–4.87) 3.92 (2.89–4.64) 3.74 (2.94–4.56)
TC:HDL-C 4.5 (3.8–5.4) 4.4 (3.3–5.4) 4.4 (3.8–5.4)
LDL-C (mmol/L) 3.58 (2.5–4.13) 3.2 (2.45–3.79) 2.84 (2.24–3.82)*
LDL-C:HDL-C 2.95 (2.48–3.74) 2.94 (1.9–3.63) 2.68 (2.1–3.36)
TG (mmol/L) 1.21 (0.83–1.63) 1.3 (1.0–2.02) 1.4 (1.07–2.08)
apoAI (g/L) 1.25 (1.11–1.41) 1.25 (1.08–1.42) 1.23 (1.10–1.41)
apoB (g/L) 0.86 (0.73–1.08) 0.80 (0.64–0.93) 0.76 (0.63–0.95)
apoB:apoAI 0.71 (0.6–0.86) 0.64 (0.46–0.78) 0.63 (0.5–0.8)*
Statistically significant differences * p <0.05 (ANOVA)
(17, 18). Iwahashi et al. (18) explored the im pact of
apoB:apoAI on the damage to cardiac func tion after
a first ST-elevation myocardial infarction. A significant
relationship between the apoB:apoAI ratio and echo -
 car diographical parameters was observed, how ever
apo lipoproteins alone and the conventional lipid pa -
ra meters did not show such associations. Ba sed on
the results of this study it was concluded that the va -
lue of apoB:apoAI ratio in ACS patients on ad mission
could predict the elevation of left ven tri cular filling
pressure 2 weeks after a first STEMI on set. These re -
sults might explain why the higher values of the
apoB:apoAI ratio were frequently followed by fatal
myocardial infar ction (18). Thus the deter mi nation of
apoB:apoAI on admission to the hospital can dis tin -
guish the patients at greatest risk.  
The superiority of apolipoprotein B, and espe cially
the apoB:apoA-I ratio in patients with the highest
cardiometabolic risk, meaning known CVD or diabetes
and two additional major risk factors such as smoking,
hypertension, or family history of premature coronary
artery disease, for assessing risk of future events and in
the secondary prevention in ACS patients seems to be
indisputable. On the basis of the data from the present
study we cannot conclude that the determination of
apo lipoproteins should be recommended for routine
clini cal use, however we may confirm that incorpo rat -
ing apoB and in particular apoB:apoA-I ratio into risk
asses sment could provide additional important infor -
ma tion on cardiovascular risk. 
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